ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics to address immune deficiencies and infectious diseases both in the United States and internationally. The company recorded a notable revenue of $426,454,000.00 showcasing its steady growth. Among its key offerings are BIVIGAM, an intravenous immune globulin (IVIG) product for treating primary humoral immunodeficiency (PI), ASCENIV, another IVIG product designed for the same condition, and Nabi-HB, indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen along with other potential exposures to Hepatitis B. Additionally, ADMA Biologics is developing a pipeline of plasma-derived therapeutics, including innovative products aimed at the treatment and prevention of S. pneumonia infections for immunoglobulin. The cost of revenue for the company is $206,901,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $282,838,000.00 reflecting its overall spending. The company's stock is identified with the symbol 'ADMA' in the market, and the weighted average number of diluted shares outstanding is 243,342,000.00 indicating potential dilution effects. Moreover, the stock is affordable at $18.68 making it suitable for budget-conscious investors seeking opportunities. With a high average trading volume of 3,061,820.00 the stock demonstrates strong liquidity, which is an advantageous factor for traders. With a mid-range market capitalization of $4,161,724,640.00 the company is a steady performer in the biopharmaceutical realm. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. This dual focus on patient needs and robust market engagement aligns ADMA Biologics as an important entity shaping the future of plasma-derived therapeutics.